永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 09-04 16:08:02

0.395

+0.000

0.00%

最高0.400	最低0.395	成交量2,000
今开0.400	昨收0.395	日振幅1.27%
总市值2.44亿	流通市值2.44亿	总股本6.18亿
成交额795.00	换手率0.00%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.395,"timestamp":1788509282055,"preClose":0.395,"halted":0,"volume":2000,"delay":0,"changeRate":0,"floatShares":618000000,"shares":618000000,"eps":-0.4908237747653806,"marketStatus":"已收盘","change":0,"latestTime":"09-04 16:08:02","open":0.4,"high":0.4,"low":0.395,"amount":795,"amplitude":0.012658,"askPrice":0.395,"askSize":89000,"bidPrice":0.38,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.3338711865037986,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.395,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.066667,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2664384172","title":"港股异动 | 部分创新药概念股走高 国家医保局称更多创新药有望纳入医保报销 医保国谈即将举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664384172?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:57","pubTimestamp":1788505030,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870661","title":"一品红（300723）披露痛风创新药AR882Ⅲ期临床研究达到主要终点，9月3日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870661?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:07","pubTimestamp":1788444437,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，一品红报收于36.6元，较前一交易日下跌0.81%，最新总市值为165.32亿元。该股当日开盘37.01元，最高37.18元，最低36.36元，成交额达2.34亿元，换手率为1.52%。近日，一品红药业集团股份有限公司全资子公司广州瑞安博开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅲ期临床试验达到主要终点。AR882在有效性和安全性方面表现良好，未出现因不良事件导致停药或死亡病例。该药为1类创新药，目前尚未实现销售，对公司近期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300042176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1574","300723","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987512","title":"创新药热浪来袭，如何把握投资机会？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987512","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664987512?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:14","pubTimestamp":1788430440,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpzpq4281019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","159992","BK1574","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664731738","title":"一品红(300723.SZ)：痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2664731738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664731738?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:47","pubTimestamp":1788428833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红 发布公告，公司全资子公司广州瑞安博医药科技有限公司牵头组织开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅱ/Ⅲ期临床试验，于近日获得顶线分析数据。初步统计结果表明，AR882在痛风伴高尿酸血症参与者中表现出积极的疗效及良好的安全性，试验结果理想，达到预期目的。AR882克服了雷西纳德和苯溴马隆的缺点，能够与尿酸转运蛋白长效结合，延长抑制作用的时间，临床结果显示其药效长达24小时。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IBBQ","BK1161","BK1574","MEDX","300723","06978","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"创新药概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664242468?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LNGR","MEDX","BK1574","159992","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奥赛图与齐鲁制药达成全人纳米抗体分子非排他授权合作，支持神经领域创新药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664782740?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","MEDX","688796","IBBQ","LNGR","01477","BK1161","06978","BK1191","02315","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"国内创新药企中报归母净利增近九成！恒生创新药ETF华泰柏瑞（520500）连续2个交易日获资金加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664500829?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520500","06978","IBBQ","MEDX","BK1574","159992","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664231028","title":"创新药企密集进入临床数据验证期，石药集团涨超4%！华宝基金港股通创新药ETF（520880）再收半年线！","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664231028?lang=zh_cn&edition=full","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日，港股创新药链继续活跃，创新药龙头公司领涨，石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%，跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示，创新药较多公司进入临床数据验证阶段，值得自下而上关注。据统计，港股通创新药ETF华宝覆盖的48家创新药研发公司中，31家上半年实现盈利，归母净利同比正增长的有33家，占比近7成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","KURE","IE0008369823.USD","LU1152091168.USD","LU1226288253.USD","LU0501845795.SGD","520880","LU1226288170.HKD","LU0072913022.USD","BK1191","SG9999004220.SGD","LU1951186391.HKD","BK1574","IE00BZ08YR35.GBP","LU0880133367.SGD","159316","IE0008368742.USD","LU2039709279.SGD","MEDX","LNGR","LU1226287792.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU1993786604.SGD","LU1960683339.HKD","LU0314109678.HKD","LU1226287529.USD","BK1515","FLHK","06978","LU1226287875.USD","LU0067412154.USD","01093","IE00B031HY20.USD","IE00BZ08YT58.USD","BK1161","LU1813983027.USD","LU0326950275.SGD","LU1328277881.USD","IE00B543WZ88.USD","IBBQ","LU1807302812.USD","BK1521","HK0000165453.HKD","LU0315179316.USD","IE00BZ08YS42.EUR","LU0140636845.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664789843","title":"股市必读：迈威生物新发布《迈威生物关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664789843","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664789843?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:22","pubTimestamp":1788369733,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，迈威生物报收于27.53元，下跌1.22%，换手率2.62%，成交量6.03万手，成交额1.67亿元。当日关注点交易信息汇总：9月2日主力资金净流入1151.02万元，占总成交额6.88%。公司公告汇总：迈威生物将于9月16日15:00–17:00参加上交所主办的科创板创新药行业集体业绩说明会，董事长、财务负责人、独立董事及董秘将出席并接受投资者提问。说明会后可通过该平台查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","02493","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843263","title":"股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843263","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664843263?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:17","pubTimestamp":1788369431,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司众生睿创于9月1日使用闲置自有资金7000万元购买结构性存款产品，期限56天，均为保本浮动收益型。产品均为保本浮动收益型，资金来源为闲置自有资金，投资期限内任一时点余额未超过董事会审批额度。公司已制定相关管理制度并采取多项风险控制措施，确保资金安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002317","BK0077","BK1574","BK0188","BK0239","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810334","title":"首个国产IL-17A/F双靶点抑制剂获批，这一40年来“有研究无产品”的靶点迎临床突破｜掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810334","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810334?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:37","pubTimestamp":1788359868,"startTime":"0","endTime":"0","summary":"半月临床试验动向根据医药魔方提供的数据，8月15日至8月28日，国家药品监督管理局药品审评中心（CDE）共披露195条创新药临床试验登记信息，其中53条为Ⅱ期及以上的关键临床试验。8月15日至8月28日，国家药品监督管理局批准8款创新药上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863103683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863103683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","LNGR","BK1574","06978","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新药：已提交自研创新药HX9428临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819950?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1191","PSYK","IBBQ","LNGR","IBBJ","02637","MEDX","159992","06978","BK1574","MDTX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897534","title":"翰森制药：创新药注射用HS-20093上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897534","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897534?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:40","pubTimestamp":1788338400,"startTime":"0","endTime":"0","summary":"9月2日，翰森制药（03692）发布公告，宣布其创新药注射用HS-20093的上市许可申请已获得中国国家药品监督管理局受理。该药物用于治疗既往含铂治疗失败的小细胞肺癌成人患者。注射用HS-20093是一款公司自主研发的B7-H3靶向抗体-药物偶联物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862792527.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862792527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","03692","LNGR","BK1161","BK1191","MEDX","BK1574","BK1589","IBBQ","BK1583","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867024","title":"这家“最会赚钱的创新药第一股”，贝达药业赴港IPO，未来悬念重重……","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867024","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664867024?lang=zh_cn&edition=full","pubTime":"2026-09-02 08:53","pubTimestamp":1788310380,"startTime":"0","endTime":"0","summary":"老药的余晖埃克替尼之于贝达药业，是起点，也是命脉。仿制药上市后几乎必然以低价渗透市场，一旦竞争充分，埃克替尼或将被迫卷入国家或地区集中带量采购，面临进一步的降价压力。招股书承认，协议项下合计人民币1.8亿元的若干监管里程碑付款已被触发，并成为公司的应付款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-02/doc-iniqkvce1333036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FRHC","BK0239","BK0060","MEDX","300558","06978","BK1161","KCE","IPOS","REDS","BK4127","159992","IBBQ","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585745","title":"迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585745","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664585745?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:51","pubTimestamp":1788274270,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，迈威生物报收于27.87元，较前一交易日下跌1.62%，最新总市值为124.5亿元。该股当日开盘28.29元，最高28.5元，最低27.61元，成交额达1.54亿元，换手率为2.4%。近日，迈威（上海）生物科技股份有限公司披露公告，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","159992","02493","BK1161","BK1574","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111865861","title":"永泰生物-B8月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1111865861","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111865861?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:42","pubTimestamp":1788252170,"startTime":"0","endTime":"0","summary":"永泰生物製藥有限公司于2026年9月1日发布截至2026年8月31日的股份变动月报表。报告显示，公司注册股本依旧为5,000,000美元，已发行股份总数617,500,800股，较上月底无新增发行或注销，股本结构维持稳定。在限售及激励方面，公司于首次公开发售前购股权计划项下，期末持有股份期权数量为9,872,850份，当月无增减变动，未因期权行使而新增发行任何股份。首次公开发售后购股权计划期末持有期权数量为0，亦无变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664088647","title":"2026版国家基药目录今起施行：4款国产创新药纳入，如何影响行业与大众？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664088647","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664088647?lang=zh_cn&edition=full","pubTime":"2026-09-01 07:16","pubTimestamp":1788218160,"startTime":"0","endTime":"0","summary":"9月1日，由国家卫生健康委、国家中医药局、国家疾控局三部门联合发布的2026版《国家基本药物目录》（简称“基药目录”）正式施行。时隔8年，基药目录再次迎来重磅扩容。官方消息显示，新版目录共收录药品794种，新增药品品种116种，包含化学药品和生物制品68种、中成药48种。调出原版目录内化学药品和生物制品2种，无中成药品种调出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860569178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860569178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","IBBQ","159992","06978","BK1161","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048920","title":"A股医药中报收官，创新药企批量扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048920","media":"全球财说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048920?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:47","pubTimestamp":1788187620,"startTime":"0","endTime":"0","summary":"01中报收官，业绩分化创新药是本轮中报业绩变化最明显的方向之一。石药创新同样依靠BD兑现实现业绩反转。一条兑现路径是海外BD授权。大额BD的价值不只是改善当期利润表，即首付款可迅速补充现金储备，海外大型药企愿意支付较高金额本身也是对国产创新药研发能力的市场化验证。BD相关收入的持续兑现能力，仍是当前观察创新药企基本面的核心落脚点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-31/doc-iniqfqsp8765429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","KURE","IBBQ","BK1574","BK1161","MEDX","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663787260","title":"英特集团：公司主要通过DTP专业药房，为创新药提供上市后的终端服务和患者管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663787260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663787260?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:48","pubTimestamp":1788162490,"startTime":"0","endTime":"0","summary":"证券之星消息，英特集团(000411)08月31日在投资者关系平台上答复投资者关心的问题。投资者提问：你好懂秘：请问公司有没有为创新药提供商业化服务？英特集团回复：您好！公司主要通过DTP专业药房，为创新药提供上市后的终端服务和患者管理。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100017338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","000411","159992","BK0250","BK0097","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663602828","title":"中国生物制药：创新药Kylo-11 I期临床数据在ESC 2026及《柳叶刀》公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2663602828","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663602828?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:03","pubTimestamp":1788134617,"startTime":"0","endTime":"0","summary":"中国生物制药：创新药Kylo-11 I期临床数据在ESC 2026及《柳叶刀》公布","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313859573668.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313859573668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","IE00BZ08YT58.USD","06978","BK1589","IBBQ","BK1521","01177","BK1161","BK1574","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","HK0000165453.HKD","MEDX","LNGR","159992","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0972},{"period":"3month","weight":-0.4437},{"period":"6month","weight":-0.8319},{"period":"1year","weight":-0.9262},{"period":"ytd","weight":-0.8652}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.024873},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.02886},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}